Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions
Open accessThe DOI matches its Crossref record; 120 of the 124 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD), once considered a rare disease, is now the most common form of dementia in the elderly population. Current drugs (cholinesterase inhibitors and glutamate antagonists) are safe but of limited benefit to most patients, offering symptomatic relief without successful cure of the disease. Since the last several decades, there has been a great need for the development of a treatment that might cure the underlying causes of AD and thereby slow its progression in vulnerable individuals. That is why phase I, II, and III studies that act on several fronts, such as cognitive improvement, symptom reduction, and enhancing the basic biology of AD, are imperative to stop the disease. This review discusses current treatment strategies, summarizing the clinical features and pharmacological properties, along with molecular docking analyses of the existing medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It modulates glutamate transmission and dopamine receptors, exhibiting certain efficacy in improving patients’ cognitive function, daily living abilities, and behavior.409,410”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [409]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These drugs primarily function by modulating neurotransmitter levels but cannot alter the course of the disease,409,411 which are instructive for designing new drugs.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [409]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828 · cited 2×
“4 [8], and the data were interpreted using Discovery Studio [9] and UCSF Chimera [10].”
MethodInfluentialTrott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412 · cited 1×
“4 [8], and the data were interpreted using Discovery Studio [9] and UCSF Chimera [10].”
MethodAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204 · cited 2×
“Tau is a protein believed to play a significant role in the progression of AD; researchers are experimenting with several methods to target tau with the goal of altering the course of the disease [84].”
BackgroundResultAcetylcholinesterase Inhibitors: Pharmacology and Toxicology
Colovic, M. B., Krstic, D. Z., Lazarevic-Pasti, T. D., Bondzic, A. M., & Vasic, V. M. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030006 · Cited by 2,611
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253 · cited 1×
“Inflammation has now been observed in numerous investigations using postmortem tissues from samples of AD patients, but the role of inflammation in AD is not yet fully understood [91,92].”
BackgroundKarran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 1×
“The amyloid cascade hypothesis is one of the signaling pathways that has been thoroughly investigated concerning AD [81].”
BackgroundAlzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Glutamate as a neurotransmitter in the healthy brain
Zhou, Y., & Danbolt, N. C. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1180-8 · Cited by 979 · cited 1×
“Glutamate transmission modulation–glutamate is the most abundant excitatory neurotransmitter in the central nervous system, with about 40% of synapses containing it [67].”
BackgroundGlutamate receptor function in learning and memory
Riedel, G. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00272-3 · Cited by 962 · cited 1×
“Numerous preclinical studies have shown that when glutamate synapses are blocked, no new memories can form [68].”
BackgroundMicroglial Activation and its Implications in the Brain Diseases
Thameem Dheen, S., Kaur, C., & Ling, E.-A. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707780597961 · Cited by 952 · cited 1×
“These molecules cause damage to neurons, leading to the development of cognitive symptoms [93].”
Background
Research works printed but not linked: 3
- Wolfe, M.S. (2018). The Molecular and Cellular Basis of Neurodegenerative Diseases: Underlying Mechanisms, Academic Press.
- BIOVIA, 2017, BIOVIA Discovery Studio Visualizer, Softw. Version, 20, 779
- Darvesh, 1998, Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation, J. Comp. Neurol., 393, 374, 10.1002/(SICI)1096-9861(19980413)393:3<374::AID-CNE8>3.0.CO;2-Z · DOI · Paper page
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“51 These drugs primarily function by modulating neurotransmitter levels but cannot alter the course of the disease, 409,411 which are instructive for designing new drugs.”
BackgroundRamakrishna, K., Nalla, L. V., Naresh, D., Venkateswarlu, K., Viswanadh, M. K., Nalluri, B. N., Chakravarthy, G., Duguluri, S., Singh, P., Rai, S. N., et al. (2023) · Diseases · doi:10.3390/diseases11030089 · Cited by 192
Baran, M. F., Keskin, C., Baran, A., Hatipoğlu, A., Yıldıztekin, M., Küçükaydın, S., Kurt, K., Hoşgören, H., Sarker, M. M. R., Sufianov, A. A., et al. (2023) · Molecules · doi:10.3390/molecules28052310 · Cited by 159
Diet and lifestyle impact the development and progression of Alzheimer’s dementia
Arora, S., Santiago, J. A., Bernstein, M., & Potashkin, J. A. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1213223 · Cited by 113
Song, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114647 · Cited by 97
Therapeutic potential of natural molecules against Alzheimer's disease via SIRT1 modulation
Zhang, M., & Tang, Z. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114474 · Cited by 74
Alkhalifa, A. E., Mokhlf, A. A., Ali, H., Al-Ghraiybah, N. F., & Syropoulou, V. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15090437 · Cited by 77
“These drugs can modestly improve cognition or behavior in mild-to-moderate AD, but do not change the underlying disease course [20].”
Effect of nutrition in Alzheimer’s disease: A systematic review
Lou, I. X., Ali, K., & Chen, Q. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1147177 · Cited by 70
Grabowska, W. A., Bijak, M., Szelenberger, R., Gorniak, L., Podogrocki, M., Harmata, P., & Cichoń, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178726 · Cited by 73
“…by focusing solely on acetylcholinesterase activity, these compounds fail to address the multifactorial nature of Alzheimer’s and related neurodegenerative diseases, where amyloid plaque formation, tau pathology, oxidative stress, and neuroinflammation all contribute to disease progression [44].”
Wu, Z., Liu, P., Huang, B., Deng, S., Song, Z., Huang, X., Yang, J., & Cheng, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-33277-x · Cited by 53
Alzola, P., Pardo, C. C., Bermejo‐Pareja, F., Sánchez‐Benavides, G., Peña‐Casanova, J., Puertas‐Martín, V., Fernández‐Calvo, B., & Contador, I. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123442 · Cited by 66
Puranik, N., & Song, M. (2024) · Molecules · doi:10.3390/molecules29235744 · Cited by 54
Kruszka, J., Martyński, J., Szewczyk‐Golec, K., Woźniak, A., & Nuszkiewicz, J. (2025) · Brain Sciences · doi:10.3390/brainsci15050485 · Cited by 47
“Recent research has explored the possibility of combining these drugs with flavonoids to enhance therapeutic efficacy through multimodal mechanisms [146,163,164].”
Islam, M. T., Aktaruzzaman, M., Saif, A., Hasan, A. R., Sourov, M. M. H., Sikdar, B., Rehman, S., Tabassum, A., Abeed-Ul-Haque, S., Sakib, M. H., et al. (2024) · RSC Advances · doi:10.1039/d4ra05073h · Cited by 41
Khamies, S. M., El-Yamany, M. F., & Ibrahim, S. M. (2024) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-024-10140-y · Cited by 32
“Unfortunately, these drugs displayed several side effects such as confusion, headache, dizziness, hallucinations, agitation, affecting cardiovascular system, and stimulating the gastrointestinal tract and bladder (Miculas et al. 2023).”
Zulfugarova, P., Zivari‐Ghader, T., Maharramova, S., Ahmadian, E., Eftekhari, A., Khalilov, R. I., Türksoy, V. A., Rosic, G. L., & Selaković, D. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1148258 · Cited by 33
“Recent research has found that HMGB1 plays a pathogenic role in memory impairment, primarily via the TLR4 and RAGE signaling pathways (Rong et al., 2021; Miculas et al., 2022).”
BackgroundCao, B., Zeng, M., Hao, F.-X., Hao, Z., Zhang, Z.-K., Liang, X.-W., Wu, Y., Zhang, Y., Feng, W., & Zheng, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115825 · Cited by 30
Research Progress on the Pathogenesis, Diagnosis, and Drug Therapy of Alzheimer’s Disease
Yang, Y., & Qiu, L. (2024) · Brain Sciences · doi:10.3390/brainsci14060590 · Cited by 23
“Donepezil is an approved drug for all stages of AD [151].”
BackgroundModulation of neural circuits by melatonin in neurodegenerative and neuropsychiatric disorders
Giri, A., Mehan, S., Khan, Z., Gupta, G. D., Narula, A. S., & Kalfin, R. E. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02939-y · Cited by 22
“Miculas et al. (2022) emphasize the lack of effective treatments for Alzheimer’s disease, currently the most prevalent form of dementia in the elderly.”
Tracing the Path between Mushrooms and Alzheimer’s Disease—A Literature Review
Silva, A. M., Preto, M., Grosso, C., Vieira, M., Delerue-Matos, C. M., Vasconcelos, V. M., Reis, M. A., Barros, L., & Martins, R. F. (2023) · Molecules · doi:10.3390/molecules28145614 · Cited by 25
Lou, I. X., Chen, J., Ali, K., Shaikh, A. L., & Chen, Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190604 · Cited by 16
Is there evidence for using ketamine among individuals with dementia?
Kapoor, A., Estevez, T. P., Chan, C. K., Yamagata, N., Doumlele, K., & Tampi, R. R. (2024) · Journal of International Medical Research · doi:10.1177/03000605241258473 · Cited by 14
“3,4 Acetylcholinesterase inhibitors and glutamate regulators are reported to delay disease progression.”
BackgroundZhang, Y., Zhao, X., Gong, L., Lai, C., Liu, J., & Xie, J. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156876 · Cited by 18
Renesteen, E., Boyajian, J. L., Islam, P., Kassab, A., Abosalha, A. K., Makhlouf, S., Santos, M., Chen, H., Shum-Tim, C., & Prakash, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115351 · Cited by 16
“Nonethe-less, one major challenge in effectively managing AD remains the limited understanding of its underlying pathology, which continues to hinder treatment breakthroughs [41].”
Li, P., He, Y., & He, M. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-06454-y · Cited by 15
Menuawy, A. E., Brüning, T., Eiriz, I., Hähnel, U., Marthe, F., Möhle, L., Górska, A. M., Santos‐García, I., Wangensteen, H., Wu, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021301 · Cited by 11
“Despite extensive research efforts, there is little to no effective curative treatment available [18].”
BackgroundAdvancing Alzheimer’s disease therapy through engineered exosomal Macromolecules
Jain, S., Murmu, A., & Chauhan, A. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149590 · Cited by 11
Aurelian, S. M., Ciobanu, A. M., Carare, R. O., Stoica, S. I., Anghelescu, A., Ciobanu, V., Onose, G., Munteanu, C., Popescu, C., Andone, I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216533 · Cited by 13
Godinez, J., Lee, C. Y., & Schwans, J. P. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129392 · Cited by 10
Review on pathogenesis and treatment of Alzheimer's disease
Cai, J., Liu, Y., & Fan, H. (2024) · Developmental Dynamics · doi:10.1002/dvdy.762 · Cited by 11
“118 New biological approaches such as gene therapy, immunotherapy, stem cell therapy, microRNA therapy, multi-omics, and probiotic therapy are the future of AD diagnosis and management.”
Reyes, C., Newby, D., Raventós, B., Verhamme, K. M. C., Mosseveld, M., Prieto‐Alhambra, D., Burn, E., & Duarte‐Salles, T. (2024) · Age and Ageing · doi:10.1093/ageing/afae106 · Cited by 8
“To date, dementia patients remain treated with acetylcholinesterase inhibitors and N-Methyl-D-Aspartate receptor antagonist, which are mainly symptomatic medications with no disease modifying effects [5].”
BackgroundModeling Inhibitory Effects of Chlorogenic Acid on Amyloid Beta Aggregation
Majid, A., & Garg, S. (2024) · Industrial & Engineering Chemistry Research · doi:10.1021/acs.iecr.4c00695 · Cited by 7
Bora, P. S., Puri, S., Singh, P. P., & Sharma, U. K. (2024) · Fitoterapia · doi:10.1016/j.fitote.2024.106279 · Cited by 9
Negru, D. C., BUNGAU, S. G., Radu, A.-F., Ţiţ, D. M., Radu, A.-F., Nistor-Cseppento, C. D., & Negru, P. A. (2024) · In Vivo · doi:10.21873/invivo.13822 · Cited by 6
Self-citationGerlai, R. T. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149795 · Cited by 6
Sri, R. S., Pavithra, T., Vinciya, T., Kumar, V. S., Harikrishnan, N., Begum, R. F., & Singh, S. A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1561702 · Cited by 11
“This restriction emphasizes how urgently therapies that focus on the intricate pathophysiological pathways of AD are needed (Miculas et al., 2022).”
Rajkumar, M., Kirubakaran, D., Govindaraj, P., Shanmugarathinam, A., Deepak, P., Rajkumar, P., Uvarajan, D., Uddandrao, V. V. S., Rajendran, M., & Balamurugan, P. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.115612 · Cited by 6
Pasala, P. K., Prasanth, D., Panda, S. P., Munnangi, V., Blessy, S., Ahmad, S. F., & Al‐Mazroua, H. A. (2025) · Asian Pacific Journal of Tropical Biomedicine · doi:10.4103/apjtb.apjtb_642_24 · Cited by 7
Bulut, Z., Karaküçük‐İyidoğan, A., Bilge, M., Sıcak, Y., Turgut‐Solak, Z. D., & Oruç‐Emre, E. E. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70124 · Cited by 5
“The current pharmacotherapy for AD symptoms has been designed on the basis of the cholinergic hypothesis and typically exhibits more selective activity against AChE than BChE [39].”
Wang, Y., Xiao, Z., Yin, H., Ren, Z., Ma, X., Wang, Y., Zhang, Y., Fu, X., Zhang, F., & Zeng, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37589 · Cited by 5
“Furthermore, there are many challenges in Clinical drug development, such as poor target specificity, strong side effects, and poor absorption through the blood-brain barrier [2 – 6].”
BackgroundKarsuntseva, E. K., Voronova, A. D., Andretsova, S. S., Shishkina, V. S., Chadin, A. V., Fursa, G. A., Fedorov, A. V., Reshetov, I. V., Stepanova, O. V., & Chekhonin, V. P. (2024) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-024-06293-8 · Cited by 5
“The accepted drug therapy of AD (donepezil, ri-vastigmine, galantamine, and memantine [4]) is aimed at the maintenance of the balance of neurotransmitters in the brain [5], but their effectiveness decreases with time and complications from adverse reactions are observed [6].”
Eranhottu, S., Cherian, T., Mohanraju, R., Devi, N. S., Sanal, J., Varghese, L. S., Ambili, P., Thomas, M., Fahmeeda Parveen, P. S., & Peijnenburg, W. J. G. M. (2025) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2025.100600 · Cited by 5
Anand, S., Kumari, N., & Amruthavarshini, S. N. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00271-8 · Cited by 4
“Collectively, these findings indicate that dysregulation of WβC signaling during aging represents a critical molecular mechanism underlying synaptic dysfunction and increased susceptibility to neurode-generation [37].”
Persistence with anti-dementia medications: a systematic review and meta-analysis
Sistanizad, M., Peterson, G. M., Ling, T. R., Salahudeen, M. S., Akondi, V., & Bezabhe, W. M. M. (2025) · Age and Ageing · doi:10.1093/ageing/afaf151 · Cited by 4
“These drugs are prescribed to alleviate and slow the progression of cognitive symptoms and enhance daily functioning in affected individuals, with no disease-modifying effects [5, 6].”
Economic Evaluation of Lecanemab for Early Symptomatic Alzheimer's Disease in South Korea
Shin, S., Kim, M., & Hong, S. H. (2025) · PharmacoEconomics - Open · doi:10.1007/s41669-025-00593-z · Cited by 8
“The recently Food and Drug Administration (FDA)- approved treatment lecanemab demonstrated the potential to modify disease progression in patients with MCI and mild AD by targeting amyloid plaques [5, 6].”
Mishra, A. K., Mishra, A., Kamal, Y. T., Kumar, A., Singh, H., Verma, S., & Khan, G. (2025) · Phytomedicine Plus · doi:10.1016/j.phyplu.2025.100877 · Cited by 5
Zyuz’kov, G. N., Miroshnichenko, L. A., Polyakova, T. Y., Simanina, E. V., & Chaikovskii, A. V. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249302264240715060630 · Cited by 5
Heise, N. V., Quast, J., & Csük, R. (2024) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2024.100200 · Cited by 4
Predictors of Cognitive Decline in Alzheimer’s Disease: A Longitudinal Bayesian Analysis
Negru, D. C., Ţiţ, D. M., Negru, P. A., Bungau, G. S., & Marin, R. C. (2025) · Medicina · doi:10.3390/medicina61050877 · Cited by 5
Self-citationAn Update on Parkinson’s Disease and its Neurodegenerative Counterparts
Adam, H., Gopinath, S. C. B., Arshad, M. K. M., Adam, T., Subramanıam, S., & Hashim, U. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230403085733 · Cited by 5
Ongtanasup, T., & Eawsakul, K. (2025) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/adpp/5528793 · Cited by 5
“Tere is presently no treatment for AD that is universally accepted as the gold standard [13, 14].”
Masullo, M., Agbangla, N. F., & Arcone, R. (2025) · RIVISTA DI STUDI SULLA SOSTENIBILITA · doi:10.3280/riss2025oa19843 · Cited by 3
Ma, T., Chang, R. C., & Macauley, S. L. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1150101 · Cited by 3
“Despite decades of research, the exact molecular/cellular mechanisms underlying AD pathogenesis remain elusive, which hampers development of effective therapeutic approaches and early diagnostic biomarkers for this devastating disease (Mullane and Williams, 2018; Alzheimer’s Association, 2022; Miculas et al., 2022).”
BackgroundKahraman, Ç., Gönülalan, E. M., Koçak, E., Gökmen, F. Ş., Gündüz, M. G., Nemutlu, E., & Çankaya, İ. İ. T. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120692 · Cited by 4
Nutrition and Neuroinflammation
Na’Allah, A., Asuku, A. O., AbdulRazaq, A., Ambali, O. A., Oyeleke, M. B., & Odetayo, A. F. (2025) · Nutritional neurosciences · doi:10.1007/978-981-95-1983-5_3 · Cited by 2
Mohamed, R. A., Abdelaziz, R. H., Mohamed, M. S., Ahmed, N. H., & Ahmed, R. M. (2025) · Next research. · doi:10.1016/j.nexres.2025.100979 · Cited by 7
Therapeutic Potential of Ishige okamurae Yendo as a Multi-Target Inhibitor Against Dementia Symptoms
Kwon, O. Y., & Lee, S. H. (2025) · Life · doi:10.3390/life15111699 · Cited by 2
“Antibodies targeting amyloid plaques and phosphorylated tau proteins have been widely explored [13,14].”
“Current and emerging drug therapies in Alzheimer’s disease: A pathophysiological Perspective”
Aparajita, A., Jain, U., & Srivastava, P. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.11.078 · Cited by 2
Sandrine, M. N. Y., Kandeda, A. K., Claude, B. D., Merveille, Y. D., Albert, A., Emmanuel, O. P., Djiogue, S., Désiré, D. D. P., Kamtchouing, P., & Elisabeth, N. B. (2023) · Asian Journal of Research in Medical and Pharmaceutical Sciences · doi:10.9734/ajrimps/2023/v12i3224 · Cited by 1
“Memory impairment treatments include aducanumab, lecanemab, donepezil, and rivastigmine, while depression treatments include imipramine, fluoxetine, and paroxetine [13-16].”
BackgroundArsito, P. N., Erviana, R., Kharismawati, G. T., & Wulanggita, U. (2024) · BIO Web of Conferences · doi:10.1051/bioconf/202413501004 · Cited by 1
Hurdles and Strategies in Treating Alzheimer’s Disease
Qureshi, T., Desale, S. E., Chidambaram, H., & Chinnathambi, S. (2024) · Springer eBooks · doi:10.1007/978-981-96-0259-9_6 · Cited by 3
Tok, F., Özer, F. A., Kuzu, Z., Sıcak, Y., Kemaloğlu, F., Baday, S., Sungur, F. A., & Öztürk, M. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2594970 · Cited by 2
Dobria, A., Suarez, A. A., Whitmarsh‐Everiss, T., Pavlinov, I., Soliz, V., Hippman, R. S., Petersson, T., Petros, Z. A., & Aldrich, L. N. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00780 · Cited by 1
Tauopathies and its therapeutic interventions in Alzheimer’s disease
Sonawane, S. K., Rangappa, N., Chidambaram, H., & Chinnathambi, S. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2025.12.001 · Cited by 1
Maehara, N., Hattori, S., Nakamura, A., Nagatoishi, S., Hirota, A., Kudo, K., Yoshikawa, Y., Matsunaga, R., Tsumoto, K., Miyakawa, T., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117468 · Cited by 1
Mahajan, E., Raja, A., Sharma, A. R., Jain, A. K., Prabha, P. K., Prakash, A., & Medhi, B. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114720 · Cited by 2
Safety and effectiveness of Donepezil and Memantine in Alzheimer's Disease
Ghosh, A. (2025) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2025.170310
Kumar, B. S., Syed, A., Ekta, Raparthi, A., Palaniappan, A., Kakde, S. P., Shreelakshmi, M. N., Biswas, S. K., Ahmed, S. R., Khan, R., et al. (2025) · medRxiv · doi:10.1101/2025.08.31.25334781 · Cited by 1
Chowdhury, T. D., Shafoyat, M. U., Hemel, N. H., Nizam, D., Sajib, J. H., Toha, T. I., Nyeem, T. A., Farzana, M., Haque, S. R., Hasan, M. M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.07.716920 · Cited by 1
Balkrishna, A., Verma, S., Singh, S. K., & Arya, V. (2023) · European Journal of Neuroscience · doi:10.1111/ejn.16050 · Cited by 1
“All currently known treatments work by altering the levels of particular neurotransmitters in the brain, principally acetylcholine (ACh) and glutamate (Miculas et al., 2022).”
BackgroundOsman, N., Awang, K., Hazni, H., Khaw, K. Y., Mak, W. Q., Tiamas, S. G., Maulana, S., Zubair, M., Pudjiastuti, P., Liew, S. Y., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4767405
Withanolide Profile and Acetylcholinesterase Inhibitory Activity of Two Argentinean Jaborosa Species
Alza, N. P., Pferschy‐Wenzig, E., Kunert, O., & Murray, A. P. (2024) · Planta Medica · doi:10.1055/a-2255-7096
Qin, W., Chen, D., Wang, Y., Liu, Z., Zhou, B., Bu, X., & Wen, G. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23800
Osman, N., Awang, K., Khaw, K. Y., Mak, W. Q., Tiamas, S. G., Maulana, S., Zubair, M., Pudjiastuti, P., Hazni, H., Liew, S. Y., et al. (2024) · Natural Product Research · doi:10.1080/14786419.2024.2394096
“Galantamine is one of the prominent drugs approved by the Food and Drug Administration (FDA) for treating mild to moderate AD, along with two other synthetic donepezil and rivastigmine (Miculas et al. 2023).”
Searching for new drugs to treat Alzheimer’s disease dementia through multiple pathways
Bai, H., & Feng, X.-F. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i1.100833
Transforming Alzheimer's Treatment: Unveiling New Potential with Drug Repurposing Strategies
Mishra, A. S., Vasanthan, M. V. M., Ghosh, B., & Sivakumar, P. M. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673341391241231054936 · Cited by 2
Davis, A., Casmedes, I. Y., & Burton, M. D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062813
“Cholinesterase inhibitors such as Donepezil, Rivastig-mine, and Galantamine only provide temporary cognitive improvement and are accompanied by unwanted side effects like nausea, vomiting, and bradycardia [166].”
From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials
Verma, M., & Singh, N. K. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01793-0
Øvrebø, T. G., Sunde, A. L., Rongve, A., Kjosavik, S. R., Dalen, I., & Oesterhus, R. (2026) · Drugs - Real World Outcomes · doi:10.1007/s40801-026-00547-9
“Symptomatic pharmacological treatments are available for AD, DLB, and PDD [8–11].”
Oriquat, G., Ali, A. M., Malathi, H., Ahmad, I. A., Maharana, L., Chauhan, A. S., Arora, V., Purohit, B., & Kumar‐Mishra, M. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05910-z
Designing intranasal formulations for Alzheimer’s disease: A material-based perspective
Chen, Y.-S., & Huang, H. (2026) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj-d-25-00208
“Therefore, a material-centric framework provides a more coherent and translationally relevant basis for understanding formulation design in AD therapy [Table 2].”
Hao, Y., Yang, H., Zhong, J., Zhang, J., He, X., & Dong, X. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1821074
Olajide, A. T., Aunsorn, S., Kehinde, S. A., Kaewmanee, T., & Chusri, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125488 · Cited by 1
“Also, they have low systemic half-lives and poor penetration across the blood–brain barrier, which hamper their long-term effectiveness [40].”
New Discoveries in the Field of Neuropharmacology
Radu, B. M., & Amuzescu, B. P. (2026) · Biomolecules · doi:10.3390/biom16060901
“Similarly, non-competitive NMDA receptor antagonists like memantine inhibit excessive glutamate-triggered neuronal calcium influx and its negative consequences [9].”
Pal, T., Mukherjee, S., Karati, D., Pahari, N., Hossain, C. M., & Naskar, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010017
Ha, N. T. T., Tuyen, N. V., Ngo, Q. A., Cham, B. T., Anh, L. T. T., Tra, N. T., Hang, N. T. M., Nam, N. T., Oanh, N. T. T., Thao, V. M., et al. (2026) · Natural Product Research · doi:10.1080/14786419.2026.2697499
Chowdhury, T. D., Shafoyat, M. U., Hemel, N. H., Nizam, D., Sajib, J. H., Toha, T. I., Nyeem, T. A., Farzana, M., Haque, S. R., Hasan, M., et al. (2026) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2026.109242 · Cited by 1
Oxidative Stress in Alzheimer’s Disease: Can Dietary Interventions Provide Neuroprotection?
Kupczyk, D., Bilski, R., Kozieł, I., Słota, A., Kurek, M., Stablewska, E., Baumgart, S., Słomka, A., & Studzińska, R. (2026) · Nutrients · doi:10.3390/nu18152436
“Therefore, increasing attention has been directed toward modifiable risk factors, including lifestyle and dietary habits, which may influence disease risk and pathogenic mechanisms [1,5,6].”
Aβ-induced CaMKII hyperactivation is associated with impaired lysosomal maturation and mitophagy
Suh, E. C., Kim, Y. A., Lee, K. E., & Park, E. (2026) · Neurochemistry International · doi:10.1016/j.neuint.2026.106252
Adhikari, S., Carlyle, B. C., & de Wet, H. (2026) · The Journal of Precision Medicine Health and Disease · doi:10.1016/j.premed.2026.100057
Sharma, N., & An, S. S. A. (2026) · Molecules · doi:10.3390/molecules31183274
“They do not stop disease progression [9].”
Kamonnat, C., Thongdechsri, S., Kraokaew, P., Niamnont, N., Sobhon, P., & Meemon, K. (2026) · Oxidative Medicine and Cellular Longevity · doi:10.1155/omcl/1471919
“Their therapeutic effects are largely palliative and vary among patients, while also being associated with potential side effects [13, 14].”
Stem Cell Therapy in Alzheimer’s Disease: a Scoping Review of Safety, Efficacy and Clinical Insights
Maity, P., Nayak, A. S., Sharma, G., Sinha, S., Nanda, K. N., Das, C. C., Das, S., Kaur, R., & Bagade, T. (2026) · Current Stem Cell Reports · doi:10.1007/s40778-026-00263-8
“The absence of a cure highlights the critical need for novel therapeutic approaches that can address the underlying pathology rather than reduce symptoms [ 8 ].”
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
“It helps patients ’ behavior, everyday life skills, and cognitive function by acting as NMDA receptor antagonist (146, 147).”
Pharmacoeconomic analysis of price disparities among anti-alzheimer drug brands in the Indian market
Mahadkar, P. U., Rane, P. S., & Vichare, S. S. (2026) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20263780
Metadata
- Authors
- Miculas, D. C., Negru, P. A., Bungau, S. G., Behl, T., Hassan, S. S. U., & Tit, D. M.
- Affiliations
- University of Oradea (RO)
- University of Petroleum and Energy Studies (IN)
- Shanghai Jiao Tong University (CN)
- Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania
- Corresponding author
- Negru, Paul Andrei
- Bungau, Simona Gabriela
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2022-12-28
- Volume
- 12
- Issue
- 1
- Pages
- 131
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC9818415
- OpenAlex
- W4313361457
- Cited by
- 96
- References
- 124
- Citations by year
- 2026: 25 · 2025: 26 · 2024: 28 · 2023: 17
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Romanian Ministry of Research, Innovation and Digitisation (29 PFE/30.12.2021)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, pharmacotherapy, cholinesterase inhibitors, glutamate receptor antagonists, disease-modifying therapy, dementia, molecular docking, drug development, cognitive impairment
- MeSH terms
- Aged, Alzheimer Disease, Cholinesterase Inhibitors, Humans, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.